september 2017. We compare the two histophatological diagnoses. Conclusions: There are very few reports of pancreatic carcinoma in the remnant pancreas after a pancreaticoduodenectomy in the literature. In most of these cases, it is for adenocarcinoma and even so difficult to assess whether the remnant pancreatic cancer is a recurrence or a second primary cancer. In our patient, the first hypothesis seems to be a new tumor.
Solitary metastatic melanoma of the pancreas is very rare. Clinical experience and the literature of surgical resection of pancreatic metastasis is also limited. We report a case of isolated metastatic melanoma with an unknown primary site.
A 64-year-old male with epigastric pain was admitted to the emergency room. He had no medical history except hypertension and right wrist fracture. CT showed 7.5 x 4.5 cm mass on pancreas body. Laboratory findings showed only slightly elevated amylase levels of 109 U/L (28< normal range < 100 U/L). Intraoperative frozen section biopsy revealed that the mass is melanoma. A distal pancreatectomy and splenectomy was performed. All resection margins and lymph nodes were negative for tumor. Immunohistochemistry detected the expression of protein S100, HMB45. A physical examination by a dermatologist and ophthalmologic examination by an ophthalmologist failed to find any evidence of a primary site. The postoperative course was uneventful. At 8 month follow-up there were no signs of recurrence.
Metastatic melanoma has a poor prognosis. There is no consensus of treatment of solitary metastatic melanoma of the pancreas. Complete surgical resection of isolated metastatic melanoma of the pancreas with an unknown primary site may improve the prognosis. Rational: Biliary self-expandable metallic stents (bSEMSs) have been proven to have longer stent patency than plastic stents (bPS) in malignant biliary obstruction and is now advise as a standard practice. The risk of tumor dislocation following bSEMS placement and associated pathological pattern has never been evaluated. This study aimed to evaluate the impact of insertion of bSEMS on pathological pattern and long-term survival of patients who underwent pancreaticoduodenectomy (PD) for resectable pancreatic ductal adenocarcinoma (PDAC). Methods: A multicenter observational study was performed using a common database of patients with opereted resectable PDAC from sixteen high-volume centers in France between 2009 and 2015. Results: Of 597 patients who underwent PD for PDAC, 197(62%) underwent preoperative endoscopic biliary drainage, including 105(51%) with SEMS and 92(49%) with PS.
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The patients without biliary drainage had a significantly better median overall survival (34,9 vs 29,5 months; p=0.004) and recurrence free survival (24,6 vs 189, months; p=0.002) than those with bSEMS. Patients with bPS had intermediate survivals without any difference with the 2 other groups.
Perineural (p=0.001) and lymphovascular (p=0.029) invasion were significantly more frequent in patients with bSEMS, but lymph node involvement and ratio were not.
Multivariate analysis showed that biliary drainage, lymph node involvement and the absence of adjuvant treatment were independently associated with poorer overall survival. Conclusions: Use of SEMS, but not PS, was associated with a poorer prognosis among patients who underwent PD for PDAC, possibly related to tumor dislocation following SEMS placement. Neoadjuvant therapy in that setting should be discussed systematically. Case report: We report the case of an 80-year-old woman with arterial hypertension and hypercholesterolemia. The patient was admitted in the gastroenterology department. The abdominal CT showed a homogeny mass in the head of the pancreas and another mass in the cecum. The technique used was a total pancreatectomy, splenectomy, cholecystectomy and a right hemicolectomy.
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The histological examination showed a MCP. Twentytwo lymph nodes were not affected, and margins of resection were not affected. Frequent PanIn Foci in HPB 2018, 20 (S2), S505eS684
Electronic Posters (EP02A-EP02F) e Pancreas S549
